Abstract Since the 2013 Supreme Court ruling on BRCA1/ BRCA2 patenting, hereditary cancer gene panels now include BRCA1 and BRCA2, making these panels an option for firsttier testing. However, questions remain about the clinical utility and implications of these panels for medical management with inclusion of genes of unknown to moderate penetrance. To better understand how use of these panels affected our practice, we reviewed patients who underwent testing in our clinic from July 1, 2013 through May 23, 2014. Indications for testing included personal and/or family history of breast and/or ovarian cancer. A total of 136 patients underwent panel testing via a single commercial laboratory; 12 (8.8 %) patients were positive for a pathogenic or likely pathogenic mutation (four BRCA2 mutations, two TP53 mutations, one CDH1 mutation, two ATM mutations, and one patient each with a CHEK2, NBN, or PALB2 mutation). Of these positive patients, 100 % met the National Comprehensive Cancer Network (NCCN) guidelines for Hereditary Breast and Ovarian Cancer genetic testing (2.2014). Mutations in seven of twelve (58 %) patients led to changes in medical management; three of seven (43 %) had a non-BRCA1 or BRCA2 gene mutation. Our findings suggest that there is clinical utility of panels that include genes of unknown to moderate penetrance.
Introduction
Breast cancer is the most prevalent cancer diagnosis in women with approximately 12 % of women developing breast cancer in their lifetime. It is also the second leading cause of cancer deaths for women, behind only lung cancer; ovarian cancer is the most deadly of the gynecological cancers (Siegel et al. 2015; Walsh et al. 2011) . Hereditary Breast and Ovarian Cancer syndrome (HBOC) is caused by mutations in a number of genes, most notably BRCA1 or BRCA2 (Gabai- Kapara et al. 2014; Walsh et al. 2010 ). The BRCA1 gene was identified in September of 1994 as a cause of hereditary breast cancer (Friedman et al. 1994) , with the identification of BRCA2 shortly thereafter (Wooster et al. 1995) . Approximately 1 in 400 individuals are carriers of a BRCA1 or BRCA2 mutation causing them to be at a significantly increased risk for various cancers including breast and ovarian cancer (Gabai-Kapara et al. 2014) . These patients are also at an increased risk for prostate cancer, male breast cancer, and pancreatic cancer (Breast Cancer Linkage 1999) . Some BRCA2 positive individuals may also have increased risks to develop malignant melanoma and other possible malignancies (Gumaste et al. 2015) . Based on results of a meta-analysis, penetrance of BRCA1 and BRCA2 mutations are high, with breast cancer risks ranging from 40-70 % by age 70 and ovarian cancer risks ranging from 15-45 % (Chen and Parmigiani 2007) .
A family history of breast cancer is considered a significant risk factor to develop the disease and it is thought that 15 % of women diagnosed with breast cancer have at least one first degree relative with breast cancer. Germline mutations in BRCA1 and BRCA2 have been associated with approximately 25 % of hereditary breast cancers and 13-15 % of ovarian cancers in patients with a family history of breast or ovarian cancer (Kean 2014; Tedaldi et al. 2014; Walsh et al. 2011) . Therefore, a large portion of this patient population with breast and/or ovarian cancer has another cause of hereditary cancer, likely due to a mutation in other susceptibility genes. The development of next generation sequencing (NGS) allowed for broader germline genetic testing for hereditary cancers and has helped identify additional genes causing hereditary breast cancer in this patient population. Expanded cancer gene panels now include multiple genes known to be associated with breast and ovarian cancers, with mutations in these genes predisposing to breast, ovarian, or other cancers at differing levels of risk. This additional information allows modification of management and screening guidelines in a timely manner while at the same time providing a cost effective way of testing, as NGS can screen many genes at the same time for a lower cost than traditional Sanger sequencing (Couch et al. 2014; Domchek et al. 2013; Easton et al. 2015; King 2014; Rainville and Rana 2014; Walsh et al. 2011) . However, the clinical utility and implications of these panels for medical management are not clear, given the lack of consensus recommendations for newly described genes and those with unknown to moderate penetrance.
We investigated how results obtained from the use of four different multi-gene panels ordered through the same commercial laboratory impacted the medical recommendations made to our patients in our large community-based hereditary cancer risk program.
Methods
We reviewed all patients who underwent genetic counseling and multi-gene panel testing at our center for a personal and/ or family history of breast and/or ovarian cancer. These patients were seen from July 1, 2013 through May 23, 2014. The multi-gene panel tests were all ordered through a single genetic testing laboratory (Ambry Genetics, Aliso Viejo, CA) by a single genetics department within a large community-based cancer center (Table 1 ). All of the panels included a minimum of six genes: BRCA1, BRCA2, CDH1, PTEN, TP53, STK11 and included a maximum of 28 depending on the panel utilized (Table 1) . The panel was selected at the discretion of the genetic counselor after discussion with the patient and evaluation of the family history for breast, ovarian, and other cancers. Patients included in this cohort consented to clinical genetic testing and agreed to participate in research, as approved by the Baylor University Medical Center's Institutional Review Board. Mutations were identified by next generation sequencing and large deletion and duplication analyses. Confirmation testing such as specific site analysis by Sanger sequenced was also performed.
The diagnostic laboratory that performed the genetic testing provided a pre-verification service where they would call each patient if the estimated out-of-pocket cost was to exceed $100. It is plausible, but not certain, that all of these patients had good or complete insurance coverage as the genetic counselor was not notified of the patients' out-of-pocket cost by the patients, nor did the patients elect to cancel the test due to outof-pocket costs.
Patient charts were reviewed and categorized according to the following: multi-gene panel test, previous genetic testing, and if the current NCCN guidelines for pursuing BRCA1 and BRCA2 genetic testing were met (Version 2.2014)(BGenetic/ Familial High-Risk Assessment: Breast and Ovarian Version 2.2014,^2014). Genetic test results were categorized into three groups: positive, variant of unknown significance (VUS) and negative. Variants, likely pathogenic (VLP) were 
Results
We identified 136 patients who had multi-gene panels sent for sequencing from July 1, 2013 to May 23, 2014 (Table 2) . These patients ranged from 25 to 85 years of age and almost all were female (133 females and 3 males). Three of the patients did not meet the NCCN guidelines for extended panel genetic testing at the time of their treatment. All three of these patients had breast cancer while in their early 50's in addition to other primary cancers, but they had no family history of cancer. One of these three individuals had melanoma at age 45, renal cell cancer at age 49, and breast cancer at age 51. Another patient had a thyroid cancer at age 46 and breast cancer at age 54. The last individual had renal cell carcinoma at age 48 and breast cancer at age 51. All three of these patients who did not meet the NCCN guidelines at the time of their genetic testing were negative for a pathogenic or VLP mutation. In our patient cohort, 122 had a diagnosis of breast cancer. The types of breast cancer varied among the patients tested, although most were estrogen and/or progesterone receptor positive (72 of 122 patients tested), 15 patients were Her2 positive (includes some that were ER + /PR + /Her2 + ), and 15 patients had triple negative breast cancer. There were seven patients with ovarian carcinoma and the remaining twenty patients had thyroid cancer, melanoma, renal cell carcinoma, basal cell carcinoma, endometrial cancer, as well as a number of other cancers (Table 2 ).
Of the patients tested, 24 had no prior diagnosis of cancer and 81 had a diagnosis of a single type of cancer. Twenty-six had a history of two cancers and the remaining five had a history of three or more cancers. Of the four genetic tests run, 48 patients underwent BRCAplus™ panel testing, 75 patients underwent BreastNext™ panel testing, eight patients underwent OvaNext™ panel testing, and five patients underwent testing with the CancerNext™ panel.
A total of 12 (8.8 %) had pathogenic mutations identified out of the 136 patients who had samples analyzed for germline mutations. These positive results included four BRCA2 mutations, two TP53 mutations, one CDH1 mutation, two ATM mutations, and one patient each with a CHEK2, NBN, or PALB2 mutation (Table 3 ). Of the patients tested, four had prior negative BRCA1 and BRCA2 sequencing and deletion/ duplication testing but on retesting had a mutation in another cancer gene of interest. Of the patients found to have a positive test result in any gene, 100 % met the NCCN guidelines for Hereditary Breast and Ovarian Cancer (HBOC) genetic testing (Version 2.2014)(BGenetic/Familial High-Risk Assessment: Breast and Ovarian Version 2.2014,^2014). The CDH1 mutation carrier did not meet NCCN guidelines for hereditary diffuse gastric cancer testing and only one of the Variants of unknown significance were identified in 22 (16.1 %) patients, one of whom had a coexisting pathogenic mutation, while 2 additional patients (1.4 %) had a VLP. Within our cohort (N = 136), 21 (15.4 %) patients had a total of 25 variants of uncertain significance (VUS) as their only abnormality (i.e. no coexisting VLP or pathogenic mutation) and 103 (75.7 %) patients had negative test results.
Testing through NGS panels identified 12 patients in our cohort of 136 (8.8 %) with an actionable test result (VLP or mutation). Of these 12 patients, 10 out of 12 (83.3 %) or 10 out of 136 (7.3 %) of the overall cohort were given new medical management recommendations based on their multigene panel test result (see Table 4 ). All of the patients with a personal history of cancer had undergone surgery for their cancer by the time of their genetic testing. Therefore, test results were not available for any of these individuals at the time of their primary cancer surgery. Seven of the 12 patients received specific recommendations for the consideration of prophylactic surgery (mastectomy, oophorectomy, or gastrectomy) in addition to recommendations for heightened surveillance in addition to or in-lieu of surgical options. Recommendations for the consideration of changes to medical management were based on NCCN guidelines V2.2014 as well as medical and family history of cancer. At the time this cohort underwent testing, turn-around times ranged from three weeks (BRCAplus™) to an average of twelve weeks for the other panels.
Of the eight patients with pathogenic or likely pathogenic mutations in genes other than BRCA1 and BRCA2, all had recommendations for changes in medical management except for one patient. This one patient died of pancreatic cancer after the results of testing were obtained, so changes in medical management were not possible to implement. All of these recommendations included either heightened breast cancer screening or consideration of prophylactic mastectomies. Patients with TP53 germline mutations were advised to avoid radiation therapy as part of their local therapy if possible. Although not included in standard recommendations for TP53 mutation carriers, both patients with TP53 mutations had family histories of gynecologic cancers (ovarian and uterine cancers). Therefore, these individuals were counseled on the possible benefits for them of hysterectomy and bilateral salpingo-oophorectomies. The individual with a CDH1 germline mutation underwent bilateral prophylactic mastectomies as well as total gastrectomy with the finding of focal hyperplasia with some atypia but negative for invasive carcinoma. For the patient with NBN mutation, there were no clinical guidelines available at the time of diagnosis. Based on a review of the literature, melanoma screening with yearly dermatologic exam (Debniak et al. 2003 ; Steffen et al. 2004 ) and age appropriate general population cancer screening was recommended.
Discussion
Two previous studies, (Doherty et al. 2015) and (Kurian et al. 2014) , examined the clinical utility of multi-gene panels in the oncology setting. Doherty et al. found that in their patient population, testing with a commercial 6 gene panel likely represented 'over testing.' At the time of publication, research was limited regarding the use of multi-gene cancer panels and their utility (Doherty et al. 2015) . Kurian et al. studied a 42 gene commercial panel in their patient population and found that mutations in genes other than BRCA1/BRCA2 did change the recommended management guidelines for those patients. Thus, these authors concluded that multi-gene panels do benefit select patients (Kurian et al. 2014) .The difference in these results may reflect the low number of genes tested in the Doherty study compared to the 42 gene panel tested by Kurian et al. There may be a critical number of genes that need to be tested in order to capture a significant number of patients with low incidence or moderate penetrance gene mutations. A multi-gene testing approach demonstrated that up to 17 % of BRCA1 and BRCA2 mutation-negative high risk breast cancer families and up to 24 % of unselected ovarian cancer cases could identify an additional mutation through panel testing (Walsh et al. 2006; Walsh et al. 2011; Walsh et al. 2010) . Limitations exist for panel testing, especially as a first-tier testing option, because they include a higher rate of variant of unknown significance test results as well as differing interpretations of the identified variants amongst laboratories performing these tests (Couch et al. 2014; Domchek et al. 2013; Easton et al. 2015) . A limitation of genetic testing is that an incorrect interpretation of the significance of a gene variant can lead to inappropriate surgery and screening recommendations (Domchek et al. 2013 ).
Recently Susswein et al. described the first ten thousand cases referred to their laboratory for germline testing for mutations in hereditary cancer risk genes (Susswein et al. 2015) . These authors demonstrated a similar rate of positive results at 9.0 % overall and 9.7 % and 13.4 % in their breast and ovarian cancer panels, respectively. Interestingly, about half of the mutations in the breast panel were in genes other than BRCA1 and BRCA2 (Susswein et al. 2015) . In the present study only four of eleven patients had mutations in the BRCA1 and BRCA2 genes; the rest of the mutations were in other breast cancer-related genes (Table 3) .
This study did not include medical recommendations provided to patient family members; future research could investigate the broader impact on family members upon learning the results from genetic testing. Our findings suggest that there is clinical utility of NGS panels for use in this patient population despite the inclusion of unknown to moderate penetrant genes and a higher rate of VUS results than single gene testing.
In most cases, patients who test positive for a mutation in one of these genes were able to make decisions regarding heightened surveillance for the associated cancers or prophylactic surgeries to help reduce the risk of cancers c au s e d b y t h e i r m u t a t i o ns ( D a l y e t a l . 2 01 4 ). Recommendations were based on guidelines where guidelines exist and on personal and family histories when no guidelines were available. This was particularly true for the patient with an NBN mutation where guidelines for management were not established. While testing is highly recommended for women with ovarian cancer irrespective of age or family history (Walsh et al. 2010 ) and extended panel testing has become increasingly common for women with breast and/or ovarian cancers, the lack of clear guidelines for heightened surveillance or preventative surgery for some gene mutations (NBN, BARD1, MRE11A, RAD50) may lead to patients' frustration and ultimately may not directly impact patients' decision making. These issues highlight the importance of pretest counseling and 2014, 2014) . These guidelines discuss the urgent need to develop appropriate management plans for patients who have mutations in less welldescribed genes, as screening and surveillance recommendations are limited, at best, for the majority of genes included on these panels (Couch et al. 2014) . Genetic testing for BRCA1/BRCA2 and consideration of other genes is recommended by NCCN for all women diagnosed with epithelial ovarian cancer, and for women with specific personal and/or family histories of cancer. Part of the difficulties of identifying mutations on these panels and determining management recommendations for patients is that the genes included may have incomplete penetrance and less defined cancer risks. More research is needed to help establish screening and surveillance guidelines for patients identified as having mutations in genes that are moderate to low penetrance. This research can help patients decide about management options including prophylactic surgeries (Couch et al. 2014) . In order for the results of genetic testing to be included as part of the decision-making process for patients, the time from sending the sample for testing to receiving the test results cannot be too long. In fact, since the patients in this study were tested, the turnaround time for multi-gene panel testing has decreased significantly, making the possibility of using the results for decisions on primary treatment more likely and feasible. Additional studies are needed to prove the utility of these multi-gene cancer tests as an important factor when planning primary cancer treatments, including chemotherapy and surgical options.
Given the complexity of the issues surrounding who should undergo NGS testing as well as the implications a pathogenic mutation in a lower penetrant gene may have, we recommend that this genetic testing should be done in close consultation with a certified genetic counselor that specializes in oncology. We anticipate that the results of ongoing studies such as the patient driven PROMPT study (Turner et al. 2011) , as well as other consortium studies will help to better clarify evidencebased recommendations on the role of heightened surveillance, prophylactic surgery, or chemoprevention in this high risk group of individuals (Katz et al. 2015) .
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